A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease

• Published in: Clinical gastroenterology and hepatology Vol. 5; no. 2; pp. 215 - 220
• Main Authors: Yacyshyn, Bruce, Chey, William Y., Wedel, Mark K., Yu, Rosie Z., Paul, David, Chuang, Emil
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2007
• Subjects: Adult; Crohn Disease - drug therapy; Crohn Disease - physiopathology; Female; Gastroenterology and Hepatology; Humans; Immunosuppressive Agents - therapeutic use; Intercellular Adhesion Molecule-1 - physiology; Male; Oligodeoxyribonucleotides, Antisense - therapeutic use; Phosphorothioate Oligonucleotides; Thionucleotides - therapeutic use; CRP; ICAM-1; TNF; CDAI; AUC; CRM; Crohn’s disease activity index; C-reactive protein; tumor necrosis factor; clinical remission; area under the curve; intercellular adhesion molecule 1
• ISSN: 1542-3565; 1542-7714; 1542-7714
• DOI: 10.1016/j.cgh.2006.11.001

Background & Aims: The aim of this study was to compare the safety and efficacy of alicaforsen, a first-generation antisense inhibitor of intercellular adhesion molecule 1, with placebo in subjects with active Crohn’s disease, a disorder in which intercellular adhesion molecule 1 is overexpresse...